Various immunotherapies were studied in the review coordinated by Teulings, including general stimulation with interferon-α (IFN- α) or interleukin-2 (IL-2), a modified oncolytic virus, and immune check-point inhibitors, the last being the standard immunotherapy for melanoma nowadays (45). This evidence concerns the gene IL2 and melanoma.